Category: Biotech
-
Biogen (BIIB.NASDAQ) and the brain death of big pharma
Ever since the greasy arrogant squirrel-faced grin of Martin Shkreli turned our collective stomach, big pharma has come under fire for their pricing practices. Pharma execs, often paid up to 300 times more than their average employee, shot back that research and development costs were crippling and all that needed to be paid for with…
-
Beyond Boobs: Else Nutrition (BABY.V) is the plant-based baby formula alternative, and it’s a big deal
The scene: Late 2005, a run down pharmacy in East Vancouver. It’s early on a Sunday morning, raining heavily outside, and I haven’t slept for three days other than in half hour spurts, usually on the couch, or even on the floor. The reason? My newborn son is screaming. He’s hungry, but he’s chewed his…
-
A Closer Look: ThinkMyco pushes the button on magic mushroom market
Psilocybin and other psychedelics are forcing their way out of prohibition as potentially viable treatments for not only depression and anxiety but also Alzheimer’s and other neurodegenerative diseases plaguing millions in North America alone. In the end, psilocybin solutions address a $300 billion dollar psychotherapy and wellness global market. Shroom Stocks’ own Ethan Reyes spoke…
-
![ProMis Neurosciences (PMN.T) and the fight against Alzheimer’s]()
ProMis Neurosciences (PMN.T) and the fight against Alzheimer’s
Someone in the world develops dementia every three seconds. Alzheimer’s disease and other dementia-related disorders affect 50M people around the world and that number is expected to double to 131.5M by 2050, that is, unless companies like ProMis Neurosciences (PMN.T) can do the unthinkable. See, our understanding of Alzheimer’s has changed dramatically since its discovery…
-
Emerald Health (EMH.V) director stands down over security clearance issues
Buried in a news release discussing a shares-for-cash payment to an acquisition target, Emerald Health (EMH.V) stated Monday it is losing a board member over Health Canada security clearance concerns. Punit Dhillon is a self-described ‘life science thought leader‘ who likes to give TED Talks and has been involved with several biomedical companies on North…
-
Three non-weed deals you don’t know: ParcelPal (PKG.C), Clear Blue (CBLU.V), and Titan Medical (TMD.T)
If I was getting paid by the number of pitches I hear, I’d be making a lot more money than I do. Often, they’re terrible. And I include ‘just okay’ in the terrible column, because if your investment pitch isn’t lights out amazing, it’s death. Sometimes I hear pitches that I really love, but the…
